Consort Medical (LON:CSRT) had its price target upped by analysts at Numis Securities from GBX 1,084 ($14.59) to GBX 1,144 ($15.40) in a report issued on Wednesday. The brokerage presently has a “hold” rating on the stock. Numis Securities’ target price would indicate a potential upside of 0.10% from the company’s previous close.

A number of other brokerages have also weighed in on CSRT. Shore Capital reaffirmed a “buy” rating on shares of Consort Medical in a report on Tuesday. N+1 Singer lowered Consort Medical to a “hold” rating in a report on Tuesday. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 1,250 ($16.82) price objective on shares of Consort Medical in a report on Thursday, November 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Consort Medical has a consensus rating of “Buy” and an average target price of GBX 1,188.17 ($15.99).

Consort Medical (CSRT) opened at GBX 1,142.83 ($15.38) on Wednesday. Consort Medical has a twelve month low of GBX 960 ($12.92) and a twelve month high of GBX 1,180 ($15.88).

ILLEGAL ACTIVITY WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at

About Consort Medical

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.

Analyst Recommendations for Consort Medical (LON:CSRT)

Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with's FREE daily email newsletter.